What dose-fractionation would you utilize to treat an oligometastatic rib lesion for durable local control?  

How would your recommendation change for a lesion within a non-radiated field versus a previously radiated field? What about an oligoprogressive lesion in a patient on systemic therapy with several other stable/responding metastases?



Answer from: Radiation Oncologist at Academic Institution